Atherosclerosis regression and high-density lipoproteins.

Area of Science:

• Cardiovascular Research
• Lipid Metabolism
• Arterial Wall Imaging

Background:

• Atherosclerosis regression is established in animal models and human studies.
• Arterial wall imaging advances understanding of regression.
• Low-density lipoprotein (LDL) lowering is the primary lipid treatment.

Purpose of the Study:

• To explore the potential of high-density lipoprotein (HDL) targeting agents as a next-generation treatment for atherosclerotic disease.
• To review current and future therapeutic strategies for HDL modulation.

Main Methods:

• Review of existing literature on atherosclerosis regression.
• Analysis of the antiatherosclerotic functions of HDL, including reverse cholesterol transport.
• Examination of current agents with documented effects and ongoing clinical trials.

Main Results:

• HDL possesses multiple antiatherosclerotic functions beyond reverse cholesterol transport.
• Nicotinic acid demonstrates documented antiatherosclerotic effects.
• Clinical trials are evaluating HDL-targeting agents in contemporary LDL treatment settings.

Conclusions:

• Targeting HDL represents a promising future direction for atherosclerotic disease treatment.
• Cholesteryl ester transfer protein inhibitors and apolipoprotein A-I mimetics are potential future HDL-based therapies.